Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

161. 乙肝丙肝检测指南:政策摘要 [Guidelines on hepatitis B and C testing : policy brief]

乙肝丙肝检测指南:政策摘要 [Guidelines on hepatitis B and C testing : policy brief] WHO IRIS: 乙肝丙肝检测指南:政策摘要 [Guidelines on hepatitis B and C testing : policy brief] Browse Related links Files in This Item: File Description Size Format 4.06 MB Adobe PDF Title: 乙肝丙肝检测指南:政策摘要 [Guidelines on hepatitis B and C testing : policy brief] Authors: Issue Date: 2017 Publisher: 马尼拉:世卫组织西太平洋区域办事处 Language: Chinese Description: 14 页 英文版由世卫组织总部出版 Subject: Context: diagnosis URI: ISBN: 9789290617938 Appears in Collections

WHO2017

162. Hepatitis : know it, treat it, prevent it [poster]

Hepatitis : know it, treat it, prevent it [poster] WHO IRIS: Hepatitis : know it, treat it, prevent it [poster] Browse Related links Files in This Item: File Description Size Format 6.57 MB Adobe PDF Title: Hepatitis : know it, treat it, prevent it [poster] Authors: Issue Date: 2017 Publisher: Manila : WHO Regional Office for the Western Pacific Language: English Description: 1 p. Subject: Context: prevention and control URI: Appears in Collections: Items in WHO IRIS are protected by copyright

WHO2017

163. Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B

Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B European Medicines Agency - - Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B Search for medicines Main navigation Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B Press release 16/12/2016 Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B Further studies needed (...) to assess risk of liver cancer with these medicines The European Medicines Agency (EMA) has confirmed its recommendation to screen all patients for hepatitis B before starting treatment with direct-acting antivirals for hepatitis C; patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines. These measures aim to minimise the risk of hepatitis B re-activation with direct-acting antivirals. Direct-acting antivirals (marketed in the EU

European Medicines Agency - EPARs2017

165. WHO guidelines on hepatitis B and C testing

WHO guidelines on hepatitis B and C testing WHO IRIS: WHO guidelines on hepatitis B and C testing Browse Related links Files in This Item: File Description Size Format 784.79 kB Adobe PDF Title: WHO guidelines on hepatitis B and C testing Authors: Issue Date: 2017 Publisher: World Health Organization Place of publication: Geneva Language: English Description: 170 p. Keywords: WHO guideline Subject: Context: diagnosis URI: ISBN: 9789241549981 License: CC BY-NC-SA 3.0 IGO License URL: Appears

WHO2017

166. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. BACKGROUND: Universal anti-hepatitis-B vaccination of infants and adolescents was implemented in Italy in 1991. We undertook a multicentre study in previously vaccinated individuals to assess the duration of immunity and need for booster, over 10 years after vaccination. METHODS: In 1212 children and 446 Italian Air Force recruits vaccinated as infants and adolescents, respectively, we (...) measured the concentrations of antibodies to hepatitis-B surface antigen (anti-HBs) and the presence of antibodies to hepatitis-B core antigen (anti-HBc) at enrollment; postimmunisation values were not available. Individuals positive for anti-HBc were tested for hepatitis B surface antigen (HBsAg) and hepatitis B viral DNA. Individuals with anti-HBs concentrations at 10 IU/L or more were regarded as protected; those with antibody less than 10 IU/L were given a booster dose and retested 2 weeks later

Lancet2017

167. HIV and hepatitis C virus RNA in seronegative organ and tissue donors.

HIV and hepatitis C virus RNA in seronegative organ and tissue donors. The objective of our study was to determine whether nucleic acid testing could detect HIV RNA or hepatitis C virus (HCV) RNA in a large series of seronegative organ and tissue donors, and whether this technique should be routinely used to improve viral safety of grafts. We studied 2236 organ donors, 636 tissue donors, and 177 cornea donors. We identified five HCV RNA-positive donors in 2119 HCV-seronegative organ donors

Lancet2017

168. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors.

T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Blood donors are routinely screened for hepatitis C virus infection. Some individuals have weak or restricted virus-specific antibody responses, and are classed as indeterminate. Such donors are almost always negative for viral RNA in blood. We postulated that previous transient virus exposure might account for some of these cases. With sensitive ex-vivo analyses of T-cell responses, we identified virus

Lancet2017

169. Dispelling myths in the treatment of hepatic encephalopathy.

Dispelling myths in the treatment of hepatic encephalopathy. CONTEXT: Guidelines for the treatment of hepatic encephalopathy suggest ammonia reduction as the main focus, based on strategies to reduce ammonia's generation and absorption in the colon by using lactulose and a reduced protein diet. STARTING POINT: Two studies provide compelling and provocative data questioning the relevance of these interventions. Bodils Als-Nielsen and colleagues, in a systematic review of randomised trials, found (...) insufficient evidence about whether non-absorbable disaccharides are beneficial (BMJ 2004; 328: 1046-50). In a small randomised study, Juan Cordoba and colleagues showed that diets with normal protein content can be administered safely during episodic hepatic encephalopathy due to cirrhosis and that protein restriction does not have any beneficial effect during such episodes (J Hepatol 2004; 41: 38-43). WHERE NEXT: Two approaches to new therapies for hepatic encephalopathy are needed. First

Lancet2017

172. Recommendations on hepatitis C screening for adults.

Recommendations on hepatitis C screening for adults. Recommendations on hepatitis C screening for adults. | National Guideline Clearinghouse success fail JUN 10 2017 2018 2019 03 Oct 2017 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed (...) In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011202 2017 Apr 24 NEATS Assessment Recommendations on hepatitis C screening for adults. Canadian Task Force on Preventive Health Care. Recommendations on hepatitis

National Guideline Clearinghouse (partial archive)2017

173. Hepatic encephalopathy

Hepatic encephalopathy Hepatic encephalopathy - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hepatic encephalopathy Last reviewed: August 2018 Last updated: December 2017 Summary A neuropsychiatric syndrome caused by acute or chronic hepatic insufficiency. Symptoms vary in severity from a mild alteration in mental state to coma but are often reversible with treatment. Causation is thought to be multi-factorial (...) , resulting in brain exposure to ammonia that has bypassed the liver through portosystemic shunting. Diagnosis is based on reported neurological deficits combined with laboratory abnormalities showing severe liver dysfunction. Treatment approaches include providing supportive care (such as preventing aspiration), correcting precipitating factors, and reducing gastrointestinal production of ammonia. Among patients with acute hepatic failure and severe encephalopathy, about 75% to 80% will develop cerebral

BMJ Best Practice2017

174. Hepatic steatosis

Hepatic steatosis Hepatic steatosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hepatic steatosis Last reviewed: August 2018 Last updated: November 2017 Summary Non-alcoholic hepatic steatosis, or non-alcoholic fatty liver disease, is the most common cause of chronic liver disease in the Western world. It is projected to become a leading indication for liver transplantation, superseding hepatitis C. The diagnosis (...) of hepatic steatosis is based on exclusion of other aetiologies, such as alcohol use, along with histology. Associated with obesity and features of the metabolic syndrome in most cases. May progress to steatohepatitis and end-stage liver disease. There are no currently recommended drug treatments. Lifestyle modification remains the first-line therapy. Definition Non-alcoholic fatty liver disease (NAFLD) is a clinico-histopathological entity that includes a spectrum of conditions characterised

BMJ Best Practice2017

175. Hepatitis C

Hepatitis C Canadian Task Force on Preventive Health Care | Hepatitis C (2017) English Menu Hepatitis C (2017) Hepatitis C (2017) Click to view article Tools Additional Documents Click to see additional documents Endorsements This Clinical Practice Guideline has been endorsed by the Nurse Practitioners’ Association of Canada (NPAC). Calculate by QxMD This guideline and KT tool(s) are available on QxMD. Click to download the app. Summary of recommendations for clinicians and policy-makers (...) This recommendation applies to asymptomatic adults who are not at elevated risk for hepatitis C. It does not apply to pregnant women or adults who are at elevated risk for hepatitis C, including individuals with current or past history of injection drug use, individuals who have been incarcerated, immigrants from hepatitis C endemic regions, individuals who have received health care where there is a lack of universal precautions, recipients of blood transfusions, blood products or organ transplant before 1992

Canadian Task Force on Preventive Health Care2017

176. Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice from the American College of Physicians and the Centers for Disease Control and Prevention

Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice from the American College of Physicians and the Centers for Disease Control and Prevention Hepatitis B Vaccination, Screening, and Linkage to Care | Annals of Internal Medicine | American College of Physicians '); } '); })(); Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN (...) IN | | Subscribe to Annals of Internal Medicine . You will be directed to acponline.org to complete your purchase. Search Clinical Guidelines | 5 December 2017 Hepatitis B Vaccination, Screening, and Linkage to Care: Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention Free Winston E. Abara, MD, PhD; Amir Qaseem, MD, PhD, MHA; Sarah Schillie, MD, MPH, MBA; Brian J. McMahon, MD; Aaron M. Harris, MD, MPH ( ) ; for the High Value Care Task Force

American College of Physicians2017

178. Management and follow up of baby of hepatitis C infected woman

Management and follow up of baby of hepatitis C infected woman Queensland Health State of Queensland (Queensland Health) 2016 http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Queensland Clinical Guidelines, Guidelines@health.qld.gov.au Queensland Clinical Guidelines www.health.qld.gov.au/qcg Management and follow up of baby of hepatitis C infected woman Queensland Clinical Guideline: Perinatal substance use: neonatal F16.38-5-V2-R21 Baby born to hepatitis C infected woman Birth (...) • Administer hepatitis B immunisation within 24 hours • Check records for maternal HBV and HIV screening Breastfeeding • Encourage and support woman • Consider expressing and discarding breast milk if nipples cracked and bleeding Hepatitis C virus RNA test at 3 months or older HCV antibody test 12-18 months • Potentially passive maternal antibody clearance • Consider HCV antibody at or after 18 months Hepatitis C RNA negative HCV antibody positive HCV antibody negative Baby is not infected Hepatitis C RNA

Queensland Health2017

179. Zepatier (Grazoprevir and Elbasvir) for chronic hepatitis C infection

Zepatier (Grazoprevir and Elbasvir) for chronic hepatitis C infection Zepatier (Grazoprevir and Elbasvir) for chronic hepatitis C infection Zepatier (Grazoprevir and Elbasvir) for chronic hepatitis C infection HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Zepatier (Grazoprevir and Elbasvir) for chronic hepatitis C infection. Lansdale (...) : HAYES, Inc. Directory Publication. 2017 Authors' conclusions Rationale: The nonstructural proteins (NS) 3, 4A, and 5A (NS3, NS4A, and NS5A) are key enzymes in hepatitis C virus (HCV) RNA replication. Drugs targeting these enzymes are expected to inhibit HCV replication, thus lowering viral loads. Technology Description: Zepatier (grazoprevir, 100 milligrams [mg] and elbasvir, 50 mg; Merck Sharp & Dohme Corp.) is a "next-generation" directacting antiviral (DAA) administered as a once-daily tablet

Health Technology Assessment (HTA) Database.2017